The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting

Psychopharmacology

Volumn 203, Issue 1, 2009, Pages 155-160

  Benedetti, Francesco ^a,b,c   Colombo, Cristina ^a,b   Pirovano, Adele ^a,b   Marino, Elena ^a,b   Smeraldi, Enrico ^a,b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b National Institute of Neuroscience   (Hungary)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Antidepressant; COMT; Dopamine; Noradrenaline; Paroxetine; Serotonin

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; FLURAZEPAM; METHIONINE; PAROXETINE; VALINE;

ADULT; ALGORITHM; ANALYSIS OF VARIANCE; ARTICLE; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG DOSE TITRATION; ENZYME ACTIVITY; FEMALE; GENOTYPE; HAMILTON SCALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOLECULAR INTERACTION; MONOTHERAPY; NEUROTRANSMISSION; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; STATISTICAL MODEL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 60449108060     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-008-1381-7     Document Type: Article

References (32)

1. R Arai N Karasawa M Geffard I Nagatsu 1995 l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study Neurosci Lett 195 195 198
2. B Arias A Serretti C Lorenzi C Gasto R Catalan L Fananas 2006 Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin J Affect Disord 90 251 256
3. BT Baune C Hohoff K Berger A Neumann S Mortensen T Roehrs J Deckert V Arolt K Domschke 2008 Association of the COMT val158met variant with antidepressant treatment response in major depression Neuropsychopharmacology 33 924 32
4. F Benedetti B Barbini C Colombo E Smeraldi 2007 Chronotherapeutics in a psychiatric ward Sleep Med Rev 11 509 22
5. J Benjamin Y Osher M Kotler I Gritsenko L Nemanov RH Belmaker RP Ebstein 2000 Association between tridimensional personality questionnaire (TPQ) traits and three functional polymorphisms: dopamine receptor D4 (DRD4), serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT) Mol Psychiatry 5 96 100
6. M Bosia M Bechi E Marino S Anselmetti S Poletti F Cocchi E Smeraldi R Cavallaro 2007 Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia Neurosci Lett 417 271 4
7. E Dremencov I Gispan-Herman M Rosenstein A Mendelman DH Overstreet J Zohar G Yadid 2004 The serotonin-dopamine interaction is critical for fast-onset action of antidepressant treatment: in vivo studies in an animal model of depression Prog Neuropsychopharmacol Biol Psychiatry 28 141 147
8. F Faul E Erdfelder AG Lang A Buchner 2007 G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences Behav Res Methods 39 175 191
9. AA Gershon T Vishne L Grunhaus 2007 Dopamine D2-like receptors and the antidepressant response Biol Psychiatry 61 145 53
10. Goodwin F, Jamison K (1990) Manic-depressive illness. Oxford University Press, Oxford
11. Hill T, Lewicki P (2006) Statistics: methods and applications. A comprehensive reference for science, industry, and data mining. General Linear Models, Chapter 18, pp 245-276. StatSoft, Tulsa (OK)
12. T Kobayashi E Hayashi M Shimamura M Kinoshita NP Murphy 2008 Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study Psychopharmacology (Berl) 197 567 580
13. A Kugaya NM Seneca PJ Snyder SA Williams RT Malison RM Baldwin JP Seibyl RB Innis 2003 Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration Neuropsychopharmacology 28 413 20
14. HM Lachman DF Papolos T Saito YM Yu CL Szumlanski RM Weinshilboum 1996 Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders Pharmacogenetics 6 243 250
15. G Lambert M Johansson H Agren P Friberg 2000 Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders Arch Gen Psychiatry 57 787 793
16. McCulloch CE, Searle SR, Neuhaus JM (2008) Generalized, linear, and mixed models, 2nd edn. Wiley, New York
17. KE Muller LM LaVange SL Ramey CT Ramey 1992 Power calculations for general linear multivariate models including repeated measures applications J Am Stat Assoc 87 1209 1226
18. DJ Nutt 2006 The role of dopamine and norepinephrine in depression and antidepressant treatment J Clin Psychiatry 67 Suppl 6 3 8
19. RG O'Brien KE Muller 1992
20. CA Olsson GB Byrnes RJ Anney V Collins SA Hemphill R Williamson GC Patton 2007 COMT Val(158)Met and 5HTTLPR functional loci interact to predict persistence of anxiety across adolescence: results from the Victorian Adolescent Health Cohort Study Genes Brain Behav 6 647 652
21. Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, Plott SJ, Nemeroff CB (2008) Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. doi: 10.1038/npp.2008.47
22. A Serretti F Benedetti R Zanardi E Smeraldi 2005 The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments Prog Neuropsychopharmacol Biol Psychiatry 29 1074 1084
23. I Smolders R Clinckers A Meurs D De Bundel J Portelli G Ebinger Y Michotte 2008 Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action Neuropharmacology 54 1017 1028
24. D Sulzer RH Edwards 2005 Antidepressants and the monoamine masquerade Neuron 46 1 2
25. A Szegedi D Rujescu A Tadic MJ Muller R Kohnen HH Stassen N Dahmen 2005 The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression Pharmacogenomics J 5 49 53
26. HY Tan JH Callicott DR Weinberger 2007 Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia Cereb Cortex 17 Suppl 1 i171 i181
27. Timm N, Kim K (2006) Univariate and multivariate general linear models: theory and applications with SAS, 2nd edn. Springer, Berlin
28. P Tremblay P Blier 2006 Catecholaminergic strategies for the treatment of major depression Curr Drug Targets 7 149 58
29. Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, TJ C (2008) Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord (in press)
30. K Yoshida H Higuchi H Takahashi M Kamata K Sato K Inoue T Suzuki K Itoh N Ozaki 2008 Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran Hum Psychopharmacol 23 121 128
31. A Zangen R Nakash DH Overstreet G Yadid 2001 Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens Psychopharmacology (Berl) 155 434 439
32. FM Zhou Y Liang R Salas L Zhang M De Biasi JA Dani 2005 Corelease of dopamine and serotonin from striatal dopamine terminals Neuron 46 65 74